Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Infinity Pharmaceuticals Inc Lowers Prior FY 2013 Net Income Guidance


Thursday, 8 Aug 2013 08:00am EDT 

Infinity Pharmaceuticals Inc announced that for fiscal 2013, it expects net loss to range from $135 million to $145 million, compared to prior expectations of $115 million to $125 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report net loss of $130 million for fiscal 2013. 

Company Quote

16.65
0.37 +2.27%
24 Dec 2014